Henry Schein, Inc.

As of November 21, 2025, Henry Schein, Inc. has shifted from a fair to an attractive valuation grade, indicating it is undervalued with a P/E ratio of 17 and a PEG ratio of 0.88, despite mixed long-term performance compared to the S&P 500.

As of October 17, 2025, Henry Schein, Inc. is fairly valued with a P/E ratio of 17, lower than Patterson Cos. but higher than Sally Beauty, and has underperformed the S&P 500 with a year-to-date return of -8.99%.

As of October 17, 2025, Henry Schein, Inc. is fairly valued with a P/E ratio of 17, an EV to EBITDA of 10.66, and a PEG ratio of 0.88, indicating mixed performance compared to peers and underperformance relative to the S&P 500.

As of October 17, 2025, Henry Schein, Inc. is fairly valued with a P/E ratio of 17 and an EV to EBITDA of 10.66, showing underperformance with a year-to-date return of -8.99% compared to the S&P 500's 13.30%.

As of September 12, 2025, Henry Schein, Inc. is in a bearish trend, indicated by negative MACD readings, bearish Bollinger Bands, and underperformance against the S&P 500, with year-to-date and one-year returns of -0.94% and -5.40%, respectively.

As of August 6, 2025, Henry Schein, Inc. is fairly valued with a P/E ratio of 17, slightly below the industry average, and has underperformed the S&P 500 with a 1-year return of -5.40%.

As of February 25, 2025, Henry Schein, Inc. is fairly valued with a P/E ratio of 17, a PEG ratio of 0.88 indicating potential undervaluation, and strong profitability metrics, despite having underperformed against the S&P 500 over the long term.

As of June 20, 2025, Henry Schein, Inc. exhibits a neutral technical stance with mixed signals, showing mildly bullish indicators on the weekly MACD and Bollinger Bands, while the monthly MACD remains bearish, indicating a lack of strong momentum.

As of March 2022, the management team of Henry Schein, Inc. includes Stanley Bergman (CEO), James Breslawski (President), Steven Paladino (CFO), Gerald Benjamin (CAO), and Mark Mlotek (CSO), along with a Board of Directors featuring Philip Laskawy as Lead Independent Director. This team is responsible for the company's strategic direction and operations.

Henry Schein, Inc. is a healthcare products and services provider for dental and medical practitioners, with net sales of $3.168 billion and a market cap of $8.54 billion as of March 2025. Key metrics include a P/E ratio of 17.00 and a return on equity of 15.64%.

As of Jun 18, Henry Schein, Inc. has a market capitalization of $8.54 billion, with net sales of $12.67 billion and a net profit of $413 million over the latest four quarters. The balance sheet shows shareholder's funds of $3.39 billion and total assets of $10.22 billion.